Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02392403




Registration number
NCT02392403
Ethics application status
Date submitted
13/03/2015
Date registered
19/03/2015
Date last updated
1/11/2018

Titles & IDs
Public title
Clinical Investigation of the Nucleus® CI532 Cochlear Implant
Scientific title
Clinical Investigation of the Nucleus® CI532 Cochlear Implant
Secondary ID [1] 0 0
CLTD5446
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hearing Loss 0 0
Condition category
Condition code
Ear 0 0 0 0
Deafness

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Nucleus CI532 cochlear implant -

Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Scalar Position of Electrode Array Determined With Computer Tomography (CT) Scan
Timepoint [1] 0 0
up to one month post-surgery
Secondary outcome [1] 0 0
Array Proximity to the Modiolus Measured Using the Wrapping Factor
Timepoint [1] 0 0
up to one month post-surgery
Secondary outcome [2] 0 0
Surgeon Questionnaire on Implant Surgery
Timepoint [2] 0 0
at time of surgery
Secondary outcome [3] 0 0
Change From Baseline in Speech Recognition in Quiet and Noise at 6 Months
Timepoint [3] 0 0
baseline and 6 months post activation
Secondary outcome [4] 0 0
Patient Reported Benefit in Health Status Assessed Via Glasgow Benefit Inventory Questionnaire
Timepoint [4] 0 0
6 months post activation
Secondary outcome [5] 0 0
Change From Baseline in Hearing Ability Assessed Via Speech Spatial Hearing Qualities Questionnaire at 6 Months
Timepoint [5] 0 0
baseline and 6 months post activation
Secondary outcome [6] 0 0
Change From Baseline in Air-conduction Pure-tone Hearing Thresholds Via an Audiogram at 6 Months
Timepoint [6] 0 0
baseline and 6 months post activation
Secondary outcome [7] 0 0
Number of Adverse Events at Surgery
Timepoint [7] 0 0
at time of surgery
Secondary outcome [8] 0 0
Number of Adverse Events Post Surgery to 6 Months Post-activation
Timepoint [8] 0 0
post surgery to 6 months post-activation

Eligibility
Key inclusion criteria
* Eighteen years of age or older at the time of implantation
* Conventional candidate for cochlear implantation with a perimodiolar electrode array according to local criteria (excepting the exclusion criteria that follow)
* Native speaker in the local language used to assess clinical performance
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Evidence of hearing loss prior to 5 years of age
* Prior cochlear implantation; i.e. having a cochlear implant in the contralateral ear, or previously implanted in either ear
* Medical or psychological conditions that contraindicate undergoing general anaesthesia or surgery
* Ossification, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by medical examination
* Hearing impairment due to lesion or neuropathy of the acoustic nerve, VIII nerve or central auditory pathway
* Active middle-ear infection
* Tympanic membrane perforation
* Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices
* Unwillingness or inability of the candidate to comply with all investigational requirements such as undergoing a post-operative digital volume tomography/ConeBeam scan
* Patients with existing Cerebral Spinal Fluid shunts or drains, existing perilymph fistula, skull fracture or Cerebral Spinal Fluid leak
* Patients with recurrent episodes of bacterial meningitis
* Pregnancy or breast-feeding
* Known allergies to components of the implant
* Wearing other active implants with known interference with cochlear implants

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2016
Sample size
Target
Accrual to date
Final
45
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
The HEARing CRC - Melbourne
Recruitment postcode(s) [1] 0 0
3010 - Melbourne
Recruitment outside Australia
Country [1] 0 0
France
State/province [1] 0 0
Midi-Pyrénées
Country [2] 0 0
Germany
State/province [2] 0 0
Baden-Württemberg
Country [3] 0 0
Germany
State/province [3] 0 0
Bavaria
Country [4] 0 0
Germany
State/province [4] 0 0
Hessen
Country [5] 0 0
Germany
State/province [5] 0 0
Niedersachsen
Country [6] 0 0
Germany
State/province [6] 0 0
Schleswig-Holstein
Country [7] 0 0
Spain
State/province [7] 0 0
Gran Canaria

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Cochlear
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The aim of this study is to investigate the clinical benefit for patients implanted with the Nucleus® CI532 cochlear implant and to demonstrate the atraumatic nature of the electrode design.

Nucleus® CI532 has a pre-curved, perimodiolar array, the EA32, which is introduced into the cochlea through a straightening sheath.
Trial website
https://clinicaltrials.gov/study/NCT02392403
Trial related presentations / publications
Hey M, Wesarg T, Mewes A, Helbig S, Hornung J, Lenarz T, Briggs R, Marx M, Ramos A, Stover T, Escude B, James CJ, Aschendorff A. Objective, audiological and quality of life measures with the CI532 slim modiolar electrode. Cochlear Implants Int. 2019 Mar;20(2):80-90. doi: 10.1080/14670100.2018.1544684. Epub 2018 Nov 22.
Public notes

Contacts
Principal investigator
Name 0 0
Chris J James, PhD
Address 0 0
Cochlear
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02392403